In vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasites

PLoS Neglected Tropical Diseases

Volumn 6, Issue 4, 2012, Pages

  Varela M, Rubén E ^a   Villa Pulgarin, Janny A ^a   Yepes, Edward ^a   Müller, Ingrid ^b   Modolell, Manuel ^c   Muñoz, Diana L ^d   Robledo, Sara M ^d   Muskus, Carlos E ^d   López Abán, Julio ^a   Muro, Antonio ^a   Vélez, Iván D ^d   Mollinedo, Faustino ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c MAX PLANCK INSTITUTE OF IMMUNOBIOLOGY AND EPIGENETICS   (Germany)

^d UNIVERSIDAD DE ANTIOQUIA   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPROTOZOAL AGENT; EDELFOSINE; ERUCYLPHOSPHOCHOLINE; MEGLUMINE ANTIMONATE; MILTEFOSINE; NITRIC OXIDE; PERIFOSINE; UNCLASSIFIED DRUG; ETHER; ETHER PHOSPHOLIPID; LIPID;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; APOPTOSIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; HAMSTER; IC 50; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; LEISHMANIA; LEISHMANIASIS; MACROPHAGE; MALE; MOUSE; NONHUMAN; PARASITE LOAD; PROMASTIGOTE; SKIN LEISHMANIASIS; ANIMAL; BAGG ALBINO MOUSE; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECT; DRUG SENSITIVITY; GROWTH, DEVELOPMENT AND AGING; PARASITOLOGY; SYRIAN HAMSTER;

ANIMALS; ANTIPROTOZOAL AGENTS; APOPTOSIS; CELL SURVIVAL; CRICETINAE; DISEASE MODELS, ANIMAL; ETHER, ETHYL; FEMALE; FLOW CYTOMETRY; LEISHMANIA; LEISHMANIASIS; LIPIDS; MACROPHAGES; MALE; MESOCRICETUS; MICE; MICE, INBRED BALB C; PARASITIC SENSITIVITY TESTS; PHOSPHOLIPID ETHERS;

EID: 84861205047     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001612     Document Type: Article

References (93)

1. WHO (2010) Control of the leishmaniases. World Health Organ Tech Rep Ser 949: 1-186.
2. Murray HW, Berman JD, Davies CR, Saravia NG, (2005) Advances in leishmaniasis. Lancet 366: 1561-1577.
3. Hotez PJ, Remme JH, Buss P, Alleyne G, Morel C, et al. (2004) Combating tropical infectious diseases: report of the Disease Control Priorities in Developing Countries Project. Clin Infect Dis 38: 871-878.
4. Alvar J, Aparicio P, Aseffa A, Den Boer M, Canavate C, et al. (2008) The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 21: 334-359.
5. van Griensven J, Balasegaram M, Meheus F, Alvar J, Lynen L, et al. (2010) Combination therapy for visceral leishmaniasis. Lancet Infect Dis 10: 184-194.
6. Mishra J, Saxena A, Singh S, (2007) Chemotherapy of leishmaniasis: past, present and future. Curr Med Chem 14: 1153-1169.
7. Sundar S, (2001) Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 6: 849-854.
8. Sundar S, Chatterjee M, (2006) Visceral leishmaniasis- current therapeutic modalities. Indian J Med Res 123: 345-352.
9. Palumbo E, (2010) Treatment strategies for mucocutaneous leishmaniasis. J Glob Infect Dis 2: 147-150.
10. Croft SL, Sundar S, Fairlamb AH, (2006) Drug resistance in leishmaniasis. Clin Microbiol Rev 19: 111-126.
11. Santos DO, Coutinho CE, Madeira MF, Bottino CG, Vieira RT, et al. (2008) Leishmaniasis treatment-a challenge that remains: a review. Parasitol Res 103: 1-10.
12. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, et al. (2002) Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347: 1739-1746.
13. Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, et al. (2004) Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 38: 1266-1272.
14. Velez I, Lopez L, Sanchez X, Mestra L, Rojas C, et al. (2010) Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. Am J Trop Med Hyg 83: 351-356.
15. Machado PR, Ampuero J, Guimaraes LH, Villasboas L, Rocha AT, et al. (2010) Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Trop Dis 4: e912.
16. Chrusciak-Talhari A, Dietze R, Chrusciak Talhari C, da Silva RM, Gadelha Yamashita EP, et al. (2011) Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania (Viannia) guyanensis in Manaus, Brazil. Am J Trop Med Hyg 84: 255-260.
17. Soto J, Rea J, Valderrama M, Toledo J, Valda L, et al. (2009) Efficacy of extended (six weeks) treatment with miltefosine for mucosal leishmaniasis in Bolivia. Am J Trop Med Hyg 81: 387-389.
18. Soto J, Toledo J, Valda L, Balderrama M, Rea I, et al. (2007) Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 44: 350-356.
19. Soto J, Berman J, (2006) Treatment of New World cutaneous leishmaniasis with miltefosine. Trans R Soc Trop Med Hyg 100 (Suppl 1): S34-40.
20. Soto J, Soto P, (2006) Oral miltefosine to treat leishmaniasis. Biomedica 26 (Suppl 1): 207-217.
21. Sundar S, Jha TK, Thakur CP, Bhattacharya SK, Rai M, (2006) Oral miltefosine for the treatment of Indian visceral leishmaniasis. Trans R Soc Trop Med Hyg 100 (Suppl 1): S26-33.
22. Bhattacharya SK, Sinha PK, Sundar S, Thakur CP, Jha TK, et al. (2007) Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis 196: 591-598.
23. Rahman M, Ahmed BN, Faiz MA, Chowdhury MZ, Islam QT, et al. (2011) Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh. Am J Trop Med Hyg 85: 66-69.
24. Sindermann H, Engel J, (2006) Development of miltefosine as an oral treatment for leishmaniasis. Trans R Soc Trop Med Hyg 100 (Suppl 1): S17-20.
25. Perez-Victoria FJ, Sanchez-Canete MP, Seifert K, Croft SL, Sundar S, et al. (2006) Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use. Drug Resist Updat 9: 26-39.
26. Seifert K, Matu S, Javier Perez-Victoria F, Castanys S, Gamarro F, et al. (2003) Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int J Antimicrob Agents 22: 380-387.
27. Seifert K, Perez-Victoria FJ, Stettler M, Sanchez-Canete MP, Castanys S, et al. (2007) Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Int J Antimicrob Agents 30: 229-235.
28. Mollinedo F, Fernandez-Luna JL, Gajate C, Martin-Martin B, Benito A, et al. (1997) Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (Edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-XL. Cancer Res 57: 1320-1328.
29. Mollinedo F, de la Iglesia-Vicente J, Gajate C, Estella-Hermoso de Mendoza A, Villa-Pulgarin JA, et al. (2010) In vitro and in vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts. Clin Cancer Res 16: 2046-2054.
30. Mollinedo F, de la Iglesia-Vicente J, Gajate C, Estella-Hermoso de Mendoza A, Villa-Pulgarin JA, et al. (2010) Lipid raft-targeted therapy in multiple myeloma. Oncogene 29: 3748-3757.
31. Gajate C, Mollinedo F, (2002) Biological activities, mechanisms of action and biomedical prospect of the antitumor ether phospholipid ET-18-OCH3 (Edelfosine), a proapoptotic agent in tumor cells. Curr Drug Metab 3: 491-525.
32. Gajate C, Mollinedo F, (2001) The antitumor ether lipid ET-18-OCH3 induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. Blood 98: 3860-3863.
33. Gajate C, Mollinedo F, (2007) Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 109: 711-719.
34. Gajate C, Del Canto-Janez E, Acuna AU, Amat-Guerri F, Geijo E, et al. (2004) Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis. J Exp Med 200: 353-365.
35. Croft SL, Snowdon D, Yardley V, (1996) The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J Antimicrob Chemother 38: 1041-1047.
36. Escobar P, Matu S, Marques C, Croft SL, (2002) Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH3 (edelfosine) and amphotericin B. Acta Trop 81: 151-157.
37. Santa-Rita RM, Henriques-Pons A, Barbosa HS, de Castro SL, (2004) Effect of the lysophospholipid analogues edelfosine, ilmofosine and miltefosine against Leishmania amazonensis. J Antimicrob Chemother 54: 704-710.
38. Cabrera-Serra MG, Lorenzo-Morales J, Romero M, Valladares B, Pinero JE, (2007) In vitro activity of perifosine: a novel alkylphospholipid against the promastigote stage of Leishmania species. Parasitol Res 100: 1155-1157.
39. Cabrera-Serra MG, Valladares B, Pinero JE, (2008) In vivo activity of perifosine against Leishmania amazonensis. Acta Trop 108: 20-25.
40. Verma NK, Dey CS, (2004) Possible mechanism of miltefosine-mediated death of Leishmania donovani. Antimicrob Agents Chemother 48: 3010-3015.
41. Paris C, Loiseau PM, Bories C, Breard J, (2004) Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrob Agents Chemother 48: 852-859.
42. Taylor VM, Munoz DL, Cedeno DL, Velez ID, Jones MA, et al. (2010) Leishmania tarentolae: utility as an in vitro model for screening of antileishmanial agents. Exp Parasitol 126: 471-475.
43. David-Cordonnier MH, Gajate C, Olmea O, Laine W, de la Iglesia-Vicente J, et al. (2005) DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin. Chem Biol 12: 1201-1210.
44. Gajate C, Santos-Beneit AM, Macho A, Lazaro M, Hernandez-De Rojas A, et al. (2000) Involvement of mitochondria and caspase-3 in ET-18-OCH3-induced apoptosis of human leukemic cells. Int J Cancer 86: 208-218.
45. Gajate C, Barasoain I, Andreu JM, Mollinedo F, (2000) Induction of apoptosis in leukemic cells by the reversible microtubule-disrupting agent 2-methoxy-5-(2′,3′,4′-trimethoxyphenyl)-2,4,6-cycloheptatrien-1-one: protection by Bcl-2 and Bcl-XL and cell cycle arrest. Cancer Res 60: 2651-2659.
46. Quesada E, Delgado J, Gajate C, Mollinedo F, Acuna AU, et al. (2004) Fluorescent phenylpolyene analogues of the ether phospholipid edelfosine for the selective labeling of cancer cells. J Med Chem 47: 5333-5335.
47. Mollinedo F, Fernandez M, Hornillos V, Delgado J, Amat-Guerri F, et al. (2011) Involvement of lipid rafts in the localization and dysfunction effect of the antitumor ether phospholipid edelfosine in mitochondria. Cell Death Dis 2: e158.
48. Henao HH, Osorio Y, Saravia NG, Gomez A, Travi B, (2004) Efficacy and toxicity of pentavalent antimonials (Glucantime and Pentostam) in an American cutaneous leishmaniasis animal model: luminometry application. Biomedica 24: 393-402.
49. Estella-Hermoso de Mendoza A, Campanero MA, de la Iglesia-Vicente J, Gajate C, Mollinedo F, et al. (2009) Antitumor alkyl ether lipid edelfosine: tissue distribution and pharmacokinetic behavior in healthy and tumor-bearing immunosuppressed mice. Clin Cancer Res 15: 858-864.
50. Gajate C, Matos-da-Silva M, Dakir E-H, Fonteriz RI, Alvarez, et al. (2012) Antitumor alkyl-lysophospholipid analogue edelfosine induces apoptosis in pancreatic cancer by targeting endoplasmic reticulum. Oncogene (In press).
51. Gajate C, Fonteriz RI, Cabaner C, Alvarez-Noves G, Alvarez-Rodriguez Y, et al. (2000) Intracellular triggering of Fas, independently of FasL, as a new mechanism of antitumor ether lipid-induced apoptosis. Int J Cancer 85: 674-682.
52. Nieto-Miguel T, Gajate C, Mollinedo F, (2006) Differential targets and subcellular localization of antitumor alkyl-lysophospholipid in leukemic versus solid tumor cells. J Biol Chem 281: 14833-14840.
53. Gajate C, Gonzalez-Camacho F, Mollinedo F, (2009) Involvement of raft aggregates enriched in Fas/CD95 death-inducing signaling complex in the antileukemic action of edelfosine in Jurkat cells. PLoS ONE 4: e5044.
54. Saugar JM, Delgado J, Hornillos V, Luque-Ortega JR, Amat-Guerri F, et al. (2007) Synthesis and biological evaluation of fluorescent leishmanicidal analogues of hexadecylphosphocholine (miltefosine) as probes of antiparasite mechanisms. J Med Chem 50: 5994-6003.
55. Mollinedo F, Martinez-Dalmau R, Modolell M, (1993) Early and selective induction of apoptosis in human leukemic cells by the alkyl-lysophospholipid ET-18-OCH3. Biochem Biophys Res Commun 192: 603-609.
56. Alonso MT, Gajate C, Mollinedo F, Modolell M, Alvarez J, et al. (1997) Dissociation of the effects of the antitumour ether lipid ET-18-OCH3 on cytosolic calcium and on apoptosis. Br J Pharmacol 121: 1364-1368.
57. Varela MR, Munoz DL, Robledo SM, Kolli BK, Dutta S, et al. (2009) Leishmania (Viannia) panamensis: an in vitro assay using the expression of GFP for screening of antileishmanial drug. Exp Parasitol 122: 134-139.
58. Kolodziej H, Kiderlen AF, (2005) Antileishmanial activity and immune modulatory effects of tannins and related compounds on Leishmania parasitised RAW 264.7 cells. Phytochemistry 66: 2056-2071.
59. Colasanti M, Gradoni L, Mattu M, Persichini T, Salvati L, et al. (2002) Molecular bases for the anti-parasitic effect of NO. Int J Mol Med 9: 131-134.
60. Ascenzi P, Bocedi A, Gradoni L, (2003) The anti-parasitic effects of nitric oxide. IUBMB Life 55: 573-578.
61. Eue I, Zeisig R, Arndt D, (1995) Alkylphosphocholine-induced production of nitric oxide and tumor necrosis factor alpha by U937 cells. J Cancer Res Clin Oncol 121: 350-356.
62. Kuhlencord A, Maniera T, Eibl H, Unger C, (1992) Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother 36: 1630-1634.
63. Le Fichoux Y, Rousseau D, Ferrua B, Ruette S, Lelievre A, et al. (1998) Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB/c mice. Antimicrob Agents Chemother 42: 654-658.
64. Murray HW, (2000) Suppression of posttreatment recurrence of experimental visceral Leishmaniasis in T-cell-deficient mice by oral miltefosine. Antimicrob Agents Chemother 44: 3235-3236.
65. Serrano-Martin X, Payares G, De Lucca M, Martinez JC, Mendoza-Leon A, et al. (2009) Amiodarone and miltefosine act synergistically against Leishmania mexicana and can induce parasitological cure in a murine model of cutaneous leishmaniasis. Antimicrob Agents Chemother 53: 5108-5113.
66. Melby PC, Chandrasekar B, Zhao W, Coe JE, (2001) The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response. J Immunol 166: 1912-1920.
67. Sacks DL, Melby PC, (2001) Animal models for the analysis of immune responses to leishmaniasis. Curr Protoc Immunol Chapter 19: Unit 19 12.
68. Hommel M, Jaffe CL, Travi B, Milon G, (1995) Experimental models for leishmaniasis and for testing anti-leishmanial vaccines. Ann Trop Med Parasitol 89 (Suppl 1): 55-73.
69. Osorio LE, Castillo CM, Ochoa MT, (1998) Mucosal leishmaniasis due to Leishmania (Viannia) panamensis in Colombia: clinical characteristics. Am J Trop Med Hyg 59: 49-52.
70. Gonzalez U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, et al. (2009) Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev pp. CD004834.
71. Gupta R, Kushawaha PK, Samant M, Jaiswal AK, Baharia RK, et al. (2012) Treatment of Leishmania donovani-infected hamsters with miltefosine: analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses. J Antimicrob Chemother 67: 440-443.
72. Sundar S, Rai M, (2005) Treatment of visceral leishmaniasis. Expert Opin Pharmacother 6: 2821-2829.
73. Chakravarty J, Sundar S, (2010) Drug resistance in leishmaniasis. J Glob Infect Dis 2: 167-176.
74. Yardley V, Ortuno N, Llanos-Cuentas A, Chappuis F, Doncker SD, et al. (2006) American tegumentary leishmaniasis: Is antimonial treatment outcome related to parasite drug susceptibility? J Infect Dis 194: 1168-1175.
75. Arevalo J, Ramirez L, Adaui V, Zimic M, Tulliano G, et al. (2007) Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis. J Infect Dis 195: 1846-1851.
76. Ephros M, Bitnun A, Shaked P, Waldman E, Zilberstein D, (1999) Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes. Antimicrob Agents Chemother 43: 278-282.
77. Lucumi A, Robledo S, Gama V, Saravia NG, (1998) Sensitivity of Leishmania viannia panamensis to pentavalent antimony is correlated with the formation of cleavable DNA-protein complexes. Antimicrob Agents Chemother 42: 1990-1995.
78. Robledo SM, Valencia AZ, Saravia NG, (1999) Sensitivity to Glucantime of Leishmania viannia isolated from patients prior to treatment. J Parasitol 85: 360-366.
79. Walker J, Saravia NG, (2004) Inhibition of Leishmania donovani promastigote DNA topoisomerase I and human monocyte DNA topoisomerases I and II by antimonial drugs and classical antitopoisomerase agents. J Parasitol 90: 1155-1162.
80. Hadighi R, Boucher P, Khamesipour A, Meamar AR, Roy G, et al. (2007) Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs. Parasitol Res 101: 1319-1322.
81. Shokri A, Sharifi I, Khamesipour A, Nakhaee N, Fasihi Harandi M, et al. (2012) The effect of verapamil on in vitro susceptibility of promastigote and amastigote stages of Leishmania tropica to meglumine antimoniate. Parasitol Res 110: 1113-1117.
82. Pandey BD, Pandey K, Kaneko O, Yanagi T, Hirayama K, (2009) Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient. Am J Trop Med Hyg 80: 580-582.
83. Calvopina M, Gomez EA, Sindermann H, Cooper PJ, Hashiguchi Y, (2006) Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment. Am J Trop Med Hyg 75: 1074-1077.
84. Zerpa O, Ulrich M, Blanco B, Polegre M, Avila A, et al. (2007) Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses. Br J Dermatol 156: 1328-1335.
85. Troya J, Casquero A, Refoyo E, Fernandez-Guerrero ML, Gorgolas M, (2008) Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients. Scand J Infect Dis 40: 78-80.
86. Sindermann H, Engel KR, Fischer C, Bommer W, (2004) Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clin Infect Dis 39: 1520-1523.
87. Mollinedo F, Gajate C, Morales AI, del Canto-Janez E, Justies N, et al. (2009) Novel anti-inflammatory action of edelfosine lacking toxicity with protective effect in experimental colitis. J Pharmacol Exp Ther 329: 439-449.
88. Mollinedo F, Janssen H, de la Iglesia-Vicente J, Villa-Pulgarin JA, Calafat J, (2010) Selective fusion of azurophilic granules with Leishmania-containing phagosomes in human neutrophils. J Biol Chem 285: 34528-34536.
89. van Zandbergen G, Klinger M, Mueller A, Dannenberg S, Gebert A, et al. (2004) Cutting edge: neutrophil granulocyte serves as a vector for Leishmania entry into macrophages. J Immunol 173: 6521-6525.
90. Tasew G, Nylen S, Lieke T, Lemu B, Meless H, et al. (2010) Systemic FasL and TRAIL neutralisation reduce leishmaniasis induced skin ulceration. PLoS Negl Trop Dis 4: e844.
91. Bomfim G, Andrade BB, Santos S, Clarencio J, Barral-Netto M, et al. (2007) Cellular analysis of cutaneous leishmaniasis lymphadenopathy: insights into the early phases of human disease. Am J Trop Med Hyg 77: 854-859.
92. Bretana A, Avila JL, Lizardo G, Convit J, Rondon AJ, (1983) Leishmania species: comparative ultrastructure of experimental nodules and diffuse human cutaneous lesions in American leishmaniases. Exp Parasitol 55: 377-385.
93. Lopez Kostka S, Dinges S, Griewank K, Iwakura Y, Udey MC, et al. (2009) IL-17 promotes progression of cutaneous leishmaniasis in susceptible mice. J Immunol 182: 3039-3046.